Sugi Predict

Sugi Predict / Compounds / SCHEMBL1645535

SCHEMBL1645535

SCHEMBL1645535

C=C1CCN(c2ccc(NC(=O)C(=O)c3c(-c4ccccc4)cc4ccccn34)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.55
▸ ALDH1A1 P00352 7/20 0.55
▸ LMNA P02545 3/20 0.55
▸ HTT P42858 3/20 0.55
▸ L3MBTL1 Q9Y468 3/20 0.53
▸ THRB P10828 1/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.51
▸ KMT2A Q03164 3/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ RAB9A P51151 5/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ GAA P10253 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ NPC1 O15118 3/20 0.36
▸ TP53 P04637 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1644926 0.91 MAPT (0.58) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL1645570 0.90 MAPT (0.58) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL1645536 0.89 MAPT (0.57) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL1646414 0.88 MAPT (0.66) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL1646045 0.87 MAPT (0.58) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL1646413 0.87 MAPT (0.56) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL2231595 0.86 ALDH1A1 (0.55) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL14195580 0.86 MAPT (0.40) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL1646722 0.85 ALDH1A1 (0.56) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL1646606 0.85 ALDH1A1 (0.53) MAPTALDH1A1LMNAHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 — — EP claimed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 — — US claimed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 — — US claimed
CN-102105170-A Antifungal combination therapy F2G LTD 2011-06-22 — — CN claimed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 — — EP claimed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 — — US claimed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 — — WO claimed
US-20230310300-A1 HAIR COLOURING COMPOSITIONS COMPRISING A BIO-BASED POLYMER AND A CROSSLINKER HFC PRESTIGE SERVICE GERMINY GMBH (DE) 2023-10-05 — — US disclosed
EP-4171500-A1 HAIR COLOURING COMPOSITIONS COMPRISING A BIO-BASED POLYMER AND A CROSSLINKER Wella Germany GmbH (DE) 2023-05-03 — — EP disclosed
US-11324688-B2 Bicomponent composition WELLA INTERNATIONAL OPERATIONS SWI (CH) 2022-05-10 — — US disclosed
US-20220054392-A1 MULTICOMPONENT IN SITU COLORATION COMPOSITION WELLA INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) 2022-02-24 — — US disclosed
US-20220016017-A1 COLOR COATINGS WITH DOWNSTREAM FEATURES HFC PRESTIGE SERVICE GERMANY GMBH (DE) 2022-01-20 — — US disclosed
WO-2022002983-A1 HAIR COLOURING COMPOSITIONS COMPRISING A BIO-BASED POLYMER AND A CROSSLINKER HFC PRESTIGE SERVICE GERMANY GMBH (DE) 2022-01-06 — — WO disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 — — US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 — — WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 — — EP disclosed
WO-2009039180-A2 COLORANTS BASED N-HALAMINES COMPOSITIONS AND METHOD OF MAKING AND USING BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-03-26 — — WO disclosed
US-20090074825-A1 COLORANTS BASED N-HALAMINES COMPOSITIONS AND METHOD OF MAKING AND USING BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-03-19 — — US disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 — — WO disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016017-A1 COLOR COATINGS WITH DOWNSTREAM FEATURES KRT18, ITGA5, FLNA MAPT 360/4885ALDH1A1 4045/4885LMNA 123/4885
US-20230310300-A1 HAIR COLOURING COMPOSITIONS COMPRISING A BIO-BASED POLYMER AND A CROSSLINKER KRT18, MKI67, IK MAPT 621/4885ALDH1A1 1521/4885LMNA 1051/4885
US-20090074825-A1 COLORANTS BASED N-HALAMINES COMPOSITIONS AND METHOD OF MAKING AND USING TYR, MPO, NISCH MAPT 3260/4885ALDH1A1 171/4885LMNA 1165/4885
US-20220054392-A1 MULTICOMPONENT IN SITU COLORATION COMPOSITION KRT18, PRKDC, VIM MAPT 817/4885ALDH1A1 2062/4885LMNA 332/4885
US-11324688-B2 Bicomponent composition KRT18, EXOSC10, EXOSC9 MAPT 1247/4885ALDH1A1 3152/4885LMNA 184/4885
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 MAPT 1771/4885ALDH1A1 2813/4885LMNA 3870/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 MAPT 2950/4885ALDH1A1 318/4885LMNA 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.